|Page (1) of 1 - 04/12/11||email article||print page|
Exelixis (EXEL) has reportedly hired Goldman Sachs (GS) to handle potential takeover bids. Bloomberg reports that the company anticipates takeover offers following positive results in a study of its experimental prostate cancer treatment, cabozantinib.
|Exelixis Reportedly Hires Goldman Sachs to Run Takeover|
Source:Copyright (2011) Market News Video.. All Rights Reserved